5C40F9B6-4A54-4861-9DE5-8852BF4B13E7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.764783180026281
- age_years
- 57
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.601
- INTERFERON_GAMMA_RESPONSE+0.582
- IL6_JAK_STAT3_SIGNALING+0.535
- ALLOGRAFT_REJECTION+0.479
- E2F_TARGETS+0.479
- INFLAMMATORY_RESPONSE+0.418
- COMPLEMENT+0.416
- MTORC1_SIGNALING+0.406
- TNFA_SIGNALING_VIA_NFKB+0.341
- G2M_CHECKPOINT+0.331
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.367
- PANCREAS_BETA_CELLS-0.365
- KRAS_SIGNALING_DN-0.352
- SPERMATOGENESIS-0.215
- WNT_BETA_CATENIN_SIGNALING-0.203
- MYOGENESIS-0.145
- APICAL_JUNCTION-0.110
- UV_RESPONSE_DN-0.088
- APICAL_SURFACE-0.077
- ESTROGEN_RESPONSE_EARLY+0.023
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 722B7A0F-BF34-4368-8CFF-944FCBC7DAC4 | — | — | 0.925 |
| 2 | 29D4AB03-5604-4AD6-AEFA-EB9C7EED7FCA | — | — | 0.924 |
| 3 | 821FCEC2-41D4-48D9-8B75-D87405D075F7 | — | — | 0.917 |
| 4 | BA28EC2F-5186-4DED-8814-5F0464AB8B87 | — | — | 0.915 |
| 5 | 4942E435-61E6-4A43-B031-4E08F0B41186 | — | — | 0.914 |
| 6 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.911 |
| 7 | 6D1D9992-DA2B-419A-A80A-9EBCDA831754 | — | — | 0.909 |
| 8 | BS_X59HSFGG | low-grade glioma | — | 0.907 |
| 9 | F42071CA-8794-4C79-8B02-8D48C70E8BA1 | — | — | 0.903 |
| 10 | FD3CFD0E-E8D9-4A57-A9F0-4FB519B7E459 | — | — | 0.902 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.601 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.582 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.535 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.479 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.479 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.418 | Idelalisib | — uncovered |
| COMPLEMENT | 0.416 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.406 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.341 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.331 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.309 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.303 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.301 | Idelalisib | — uncovered |
| APOPTOSIS | 0.297 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.295 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.290 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.289 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.284 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.275 | Inavolisib | — uncovered |